Elan Pharmaceuticals, Inc.

Lycera Corporation

Sugen Incorporated

Matthew N Mattson

Gary D Glick

Simeon Bowers

Roy K Hom

Albert W Garofalo

Chad A Van Huis

Andrei William Konradi

Christopher Michael Semko

Ying-Zi Xu

Jing Wu

Clarke Bentley Taylor

Alexander Ross Hurd

Anh P Truong

Martin Neitzel

William L Thomas

Peng Cho Tang

Thomas Daniel Aicher

Congxin Liang

Arthur Glenn Romero

Darren B Dressen

Peter Laurence Toogood

Zhan Wang

Chad A VanHuis

Tomas Vojkovsky

Carl J Kaub

Huiping Guan

Karin Ann Stein

Erik Krogh-Jespersen

Carl Kaub

Alexander R Hurd

William David Thomas

The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR&#x3b3; activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.

N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ROR&#x3b3; activity and the treatment of disease

The invention provides pyridonyl guanidine compounds that inhibit FF-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

[object Object]

The invention provides compounds of Formula I wherein A, Y, R, R, R, and Rare as described in the specification. Compounds of Formula I are useful in treating and/or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of preparing compounds of Formula I, and methods of treating cognitive disorders, such as Alzheimer's disease.

Pyrazolopyrrolidines as inhibitors of gamma secretase

The invention provides N-cyclic sulfonamido compounds and salts of Formula I:  wherein A is as described in the specification and Rand Rcombine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.

Bridged N-cyclic sulfonamido inhibitors of gamma secretase

The invention provides N-cyclic sulfonamido compounds and salts of Formula I: 

The present invention relates to certain 3-&lsqb;4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene&rsqb;-2-indolinone derivatives that inhibit kinases, in particular VEGFR and/or PDGFR kinases. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.

3-&lsqb;4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene&rsqb;-2- indolinone derivatives as kinase inhibitors

Growing community of inventors

Santa Clara, CA, United States of America

Matthew N Mattson